The inactive carriers have a significant impact on clinically obtainable concentrations. As CBD is widely sold as a preparation in an edible oil, we analyzed flavored commercial hemp oils and found a CBD content of only 0. The purity of CBD and, in particular, the composition of the materials labelled as CBD are also important, especially in light of our findings suggesting that other cannabinoids such as THC might act to counter CBD antiviral efficacy.
This essentially eliminates the feasibility of marijuana serving as an effective source of antiviral CBD, in addition to issues related to its legal status. Finally, other means of CBD administration such as vaping and smoking raise concerns about potential lung damage. As the clearance rates for CBD in plasma are substantially lower in humans than mice, we would suggest moving to clinical trials rather than doing preclinical studies in animal models The necessary human in vivo concentration and optimal route and formulation remain to be defined.
We strongly caution against the urge to take CBD in presently available formulations as a preventative or treatment therapy at this time, especially without the knowledge of a rigorous randomized clinical trial with this natural product We thank Dominique Missiakas for facilitating access to the University of Chicago Howard Taylor Ricketts Facility by providing protocols and trained scientists. We also thank Nicole Rosner and Kathleen Cagney for proposing and facilitating analysis of clinical data, and Mark Ratain for consideration of pharmacokinetic issues.
Cleveland, OH. Data and materials availability: All data, code, and materials used in the analysis will be available in some form to any researcher for purposes of reproducing or extending the analysis except when limited by materials transfer agreements MTAs.
National Center for Biotechnology Information , U. Version 1. Preprints have not been peer reviewed. Jones , 7 J. Michael Millis , 8 Bryan C. Oakes , 5 Guido F. Pauli , 4 David O. Thomas J. Brent Friesen. Krysten A. Michael Millis. Bryan C. Scott A. Guido F. David O. Author information Copyright and License information Disclaimer. Co-corresponding authors. Copyright notice. The complete version history of this preprint is available at bioRxiv.
Associated Data Supplementary Materials Supplement 1. Open in a separate window. CBD promotes host cell interferon responses and inhibits viral induction of cytokines. Supplementary Material Supplement 1 Click here to view. Footnotes Data and materials availability: All data, code, and materials used in the analysis will be available in some form to any researcher for purposes of reproducing or extending the analysis except when limited by materials transfer agreements MTAs.
Supplementary Materials Materials and Methods Figs. S1 to S12 Table S1. Weiss S. Adv Virus Res 81 , 85— Galloway S. Hoffmann M. Cell , — e Jaimes J. SSRN , Matsuyama S. Wang R. Schneider W.
Daniloski Z. Cell , 92— e Kneller D. Nature communications 11 , Osipiuk J. Nature communications 12 , Nelson K. J Med Chem 63 , — Marker D. J Neurosci 33 , — Abu Aboud O. Mol Cancer Ther 15 , — Sekar K. FRes 8 , Anil S. Sci Rep 11 , Crawford K. Viruses 12 , Haller O. Virology , — Blanco-Melo D. Nucleic Acids Res 44 , D— Zhou Q. Front Immunol 11 , Muthumalage T. Toxicol Appl Pharmacol , Sorkin B. Faseb J 34 , 41—65 Formats: Article PDF 2. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement.
Neurosci Lett ; Cannabidiol: a promising new drug for neurodegenerative disorders? CNS Neurosci Ther ; Bisogno T, Di Marzo Y. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des ; Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
Rev Bras Psiquiatr ; Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci ; Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med ; Pickens JT.
Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content. Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology Berl ; Karler R, Turkanis SA. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci ; Anticonvulsant interaction of cannabidiol and ethosuximide in rats.
J Pharm Pharmacol ; Consroe P, Wolkin A. Cannabidiol-antiepilpetic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther ; Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. Assessing antidepressant activity in rodents: recent developments and future needs. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
Pharmacol Biochem Behav ; Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats.
FEBS Lett ; Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One ;6:e Influence of cannabidiol on deltatetrahydrocannabinol effects. Clin Pharmacol Ther ; Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.
Cannabidiol inhibits the hyperlocomotion induced by psychomimetic drugs in mice. Eur J Pharmacol ; Int J Neuropsychopharmacol ; Effects of cannabidiol in animal models predictive of antipsychotic activity. Cannabidiol reverses the reduction in social interaction produced by low dose Delta-tetrahydrocannabinol in rats. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol ; Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Cannabidiol inhibitory effect on marble-burying behavior: involvement of CB1 receptors. Behav Pharmacol ; Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology ; Behav Pharmacol ;S Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats.
Behav Brain Res ; Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry ; Pharmacological characterization of cannabinoids in the elevated plus maze. Antianxiety effect of cannabidiol in the elevated plus-maze.
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol ; Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol ; Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol ; Cannabidiol attenuates high glucose-induces endothelial cell inflammatory response and barrier disruption.
Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type 1 diabetic peripheral neuropathic pain. Mol Pain ; Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med Berl ; A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol ; J Neurochem ; Cannabidiol, a non-psychoactive cannabinoid compound inhibits human glioma cell migration and invasiveness.
A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther ; Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol ; Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.
Breast Cancer Res Treat ; Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Cannabidiol as a potential anticancer drug. Br J Clin Pharmacol ; Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
Schizophr Res ; Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol ; A placebo-controlled, parallel group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex nabiximols. Mult Scler ; An open-label study of cannabis-based extracts for bladder dysfuntion in advanced multiple sclerosis. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
Long-term use of a cannabis-based treatment in spasticity and other symptoms in multiple sclerosis. Eur J Neurol ; GW Pharmaceuticals Web site. Accessed: May 31, Natural Medicines Web site. Accessed May 31, Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol ;7 1 Suppl Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates.
Res Commun Chem Pathol Pharmacol ; Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos ; Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci ; Neural basis of anxiolytic effects of cannabidiol CBD in generalized social anxiety disorder: a preliminary report. Characterization of cannabidiol-mediated cytochrome P inactivation. Harvey DJ. Absorption, distribution, and biotransformation of the cannabinoids.
Marijuana and Medicine. Potent inhibition of human cytochrome P 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci ;88 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Differential inhibition of human cytochrome P 2A6 and 2B6 by major phytocannabinoids.
Forensic Toxicol ; Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes.
Cannabidiol for the treatment of psychosis in Parkinson's disease. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav ; Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delat9-tetrahydrocannabivarin. The efficacy of cannabidiol in the treatment of schizophrenia - a translational approach. Schizophr Bull ;37 Suppl 1 Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Transl Psychiatry ;2:e Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology ; Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Braz J Med Biol Res ; Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant.
Marijuana '90 International Conference on Cannabis and Cannabinoids ; Srivastava, M. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology ; Cunha, J. Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
Pharmacology ; Hypnotic and antiepileptic effects of cannabidiol. Zuardi, A. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Ames, F. Anticonvulsant effect of cannabidiol. Ohlsson, A. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Environ Mass Spectrom. Wade, D. Meta-analysis of the efficacy and safety of Sativex nabiximols , on spasticity in people with multiple sclerosis.
Collin, C. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Crippa, J. Cannabis and anxiety: a critical review of the evidence. Consroe, P. Controlled clinical trial of cannabidiol in Huntington's disease.
Pharmacol Biochem. Harvey, D. Comparative metabolism of cannabidiol in dog, rat and man. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Massi, P. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol. Life Sci. Weiss, L. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity ; Watzl, B. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro.
Int J Immunopharmacol. Barnes, M. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on patients. Iuvone, T. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem.
0コメント